# Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Canonical URL: https://biopharmsignal.com/news/BMY/bristol-myers-squibb-provides-update-on-the-first-phase-3-yellowstone-trial-evaluating-oral-zeposia-ozanimod-in-patients-with-moderate-to-severe-active-crohn-s-disease
Ticker: BMY
Company: BMYBristol-Myers Squibb Company
Source: BMYBristol-Myers Squibb Company
Published: 2024-03-28 20:01 EST
Original Source URL: https://news.bms.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-13 10:59 EST — [U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma](https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-applica-b21b9788) — Source: BMYBristol-Myers Squibb Company
- 2026-06-18 10:59 EST — [Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-second-quarter-2026-on-july-30-2026-e7e58681) — Source: BMYBristol-Myers Squibb Company
- 2026-06-17 20:16 EST — [Bristol Myers Squibb Announces Dividend](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-dividend-f5175d84) — Source: BMYBristol-Myers Squibb Company
- 2026-06-08 10:59 EST — [Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease](https://biopharmsignal.com/news/BMY/mariska-hargitay-partners-with-bristol-myers-squibb-for-investigating-myeloma-aw-222e93ab) — Source: BMYBristol-Myers Squibb Company
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)